Annual CFF
$60.33 M
+$11.36 M+23.20%
September 30, 2024
Summary
- As of February 7, 2025, OTLK annual cash flow from financing activities is $60.33 million, with the most recent change of +$11.36 million (+23.20%) on September 30, 2024.
- During the last 3 years, OTLK annual CFF has risen by +$4.13 million (+7.36%).
- OTLK annual CFF is now at all-time high.
Performance
OTLK Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
-$115.00 K
-$4.42 M-102.67%
September 1, 2024
Summary
- As of February 7, 2025, OTLK quarterly cash flow from financing activities is -$115.00 thousand, with the most recent change of -$4.42 million (-102.67%) on September 1, 2024.
- Over the past year, OTLK quarterly CFF has dropped by -$111.80 thousand (-3493.75%).
- OTLK quarterly CFF is now -100.17% below its all-time high of $66.66 million, reached on December 31, 2021.
Performance
OTLK Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$60.33 M
-$2.54 M-4.04%
September 1, 2024
Summary
- As of February 7, 2025, OTLK TTM cash flow from financing activities is $60.33 million, with the most recent change of -$2.54 million (-4.04%) on September 1, 2024.
- Over the past year, OTLK TTM CFF has increased by +$55.21 million (+1078.28%).
- OTLK TTM CFF is now -48.22% below its all-time high of $116.50 million, reached on December 31, 2021.
Performance
OTLK TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
OTLK Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +23.2% | -3493.8% | +1078.3% |
| 3 y3 years | +7.4% | -103.0% | +7.4% |
| 5 y5 years | +54.6% | -101.1% | +74.1% |
OTLK Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +23.2% | -100.2% | +99.0% | -48.2% | +1078.3% |
| 5 y | 5-year | at high | +62.1% | -100.2% | +99.0% | -48.2% | +1078.3% |
| alltime | all time | at high | +425.8% | -100.2% | +99.0% | -48.2% | +1543.6% |
Outlook Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | $60.33 M(+23.2%) | - | - |
| Sep 2024 | - | -$115.00 K(-102.7%) | $60.33 M(-4.0%) |
| Jun 2024 | - | $4.31 M(-92.3%) | $62.87 M(+1.6%) |
| Mar 2024 | - | $56.14 M(<-9900.0%) | $61.86 M(+1108.1%) |
| Dec 2023 | - | -$3200.00(-100.1%) | $5.12 M(-89.5%) |
| Sep 2023 | $48.97 M(-17.8%) | $2.42 M(-26.5%) | $48.97 M(+1.7%) |
| Jun 2023 | - | $3.30 M(-652.0%) | $48.17 M(+43.5%) |
| Mar 2023 | - | -$597.10 K(-101.4%) | $33.57 M(-8.7%) |
| Dec 2022 | - | $43.85 M(+2596.3%) | $36.78 M(-38.3%) |
| Sep 2022 | $59.59 M(+6.0%) | $1.63 M(-114.4%) | $59.59 M(-3.5%) |
| Jun 2022 | - | -$11.30 M(-533.5%) | $61.74 M(-18.5%) |
| Mar 2022 | - | $2.61 M(-96.1%) | $75.76 M(-35.0%) |
| Dec 2021 | - | $66.66 M(+1665.7%) | $116.50 M(+107.3%) |
| Sep 2021 | $56.19 M(+51.0%) | $3.78 M(+39.0%) | $56.19 M(+5.9%) |
| Jun 2021 | - | $2.72 M(-93.7%) | $53.08 M(-30.6%) |
| Mar 2021 | - | $43.35 M(+581.9%) | $76.52 M(+75.6%) |
| Dec 2020 | - | $6.36 M(+862.0%) | $43.58 M(+17.1%) |
| Sep 2020 | $37.21 M(-4.7%) | $660.80 K(-97.5%) | $37.21 M(+2.0%) |
| Jun 2020 | - | $26.16 M(+151.4%) | $36.48 M(+5.3%) |
| Mar 2020 | - | $10.40 M(<-9900.0%) | $34.65 M(+13.7%) |
| Dec 2019 | - | -$8300.00(-87.9%) | $30.49 M(-21.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2019 | $39.03 M(+13.6%) | -$68.80 K(-100.3%) | $39.03 M(+0.9%) |
| Jun 2019 | - | $24.33 M(+290.1%) | $38.67 M(+33.8%) |
| Mar 2019 | - | $6.24 M(-26.9%) | $28.91 M(+28.6%) |
| Dec 2018 | - | $8.53 M(-2119.4%) | $22.48 M(-34.6%) |
| Sep 2018 | $34.35 M(+106.6%) | -$422.30 K(-102.9%) | $34.35 M(-9.0%) |
| Jun 2018 | - | $14.56 M(-7867.4%) | $37.76 M(+30.4%) |
| Mar 2018 | - | -$187.50 K(-100.9%) | $28.97 M(-7.5%) |
| Dec 2017 | - | $20.40 M(+582.3%) | $31.31 M(+88.3%) |
| Sep 2017 | $16.63 M(-58.3%) | $2.99 M(-48.2%) | $16.63 M(+26.6%) |
| Jun 2017 | - | $5.77 M(+167.5%) | $13.14 M(-62.0%) |
| Mar 2017 | - | $2.16 M(-62.3%) | $34.58 M(-5.8%) |
| Dec 2016 | - | $5.72 M(-1232.5%) | $36.69 M(-8.0%) |
| Sep 2016 | $39.86 M(-7.3%) | -$504.80 K(-101.9%) | $39.86 M(-31.7%) |
| Jun 2016 | - | $27.21 M(+537.0%) | $58.37 M(+17.6%) |
| Mar 2016 | - | $4.27 M(-51.9%) | $49.64 M(+2.9%) |
| Dec 2015 | - | $8.89 M(-50.6%) | $48.22 M(+12.1%) |
| Sep 2015 | $43.00 M(+274.8%) | $18.00 M(-2.6%) | $43.00 M(+72.0%) |
| Jun 2015 | - | $18.48 M(+547.7%) | $25.00 M(+283.3%) |
| Mar 2015 | - | $2.85 M(-22.3%) | $6.52 M(+77.7%) |
| Dec 2014 | - | $3.67 M | $3.67 M |
| Sep 2014 | $11.47 M | - | - |
FAQ
- What is Outlook Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Outlook Therapeutics?
- What is Outlook Therapeutics annual CFF year-on-year change?
- What is Outlook Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Outlook Therapeutics?
- What is Outlook Therapeutics quarterly CFF year-on-year change?
- What is Outlook Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Outlook Therapeutics?
- What is Outlook Therapeutics TTM CFF year-on-year change?
What is Outlook Therapeutics annual cash flow from financing activities?
The current annual CFF of OTLK is $60.33 M
What is the all time high annual CFF for Outlook Therapeutics?
Outlook Therapeutics all-time high annual cash flow from financing activities is $60.33 M
What is Outlook Therapeutics annual CFF year-on-year change?
Over the past year, OTLK annual cash flow from financing activities has changed by +$11.36 M (+23.20%)
What is Outlook Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of OTLK is -$115.00 K
What is the all time high quarterly CFF for Outlook Therapeutics?
Outlook Therapeutics all-time high quarterly cash flow from financing activities is $66.66 M
What is Outlook Therapeutics quarterly CFF year-on-year change?
Over the past year, OTLK quarterly cash flow from financing activities has changed by -$111.80 K (-3493.75%)
What is Outlook Therapeutics TTM cash flow from financing activities?
The current TTM CFF of OTLK is $60.33 M
What is the all time high TTM CFF for Outlook Therapeutics?
Outlook Therapeutics all-time high TTM cash flow from financing activities is $116.50 M
What is Outlook Therapeutics TTM CFF year-on-year change?
Over the past year, OTLK TTM cash flow from financing activities has changed by +$55.21 M (+1078.28%)